Senolytic Drugs & the Fight Against Aging with Robin Mansukhani | 159 | Learning With Lowell

February 14, 2023

Dive into the research that Robin and his team have done in-house and their secret sauce, as well as exploring the current state of research on senescent cell elimination and its potential impact on healthspan and lifespan. Robin will also share his thoughts on the development pipeline for Deciduous Therapeutics’ immune mediated senolysis drugs, and how they differ from other companies in the field of immune mediated senolysis.

Robin Mansukhani links

https://www.linkedin.com/in/robin-mansukhani-8633653/

https://www.deciduoustx.com/

PODCAST INFO:

The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn’t normally ever get to hear. The Host of the show – Lowell Thompson- is a lifelong autodidact, serial problem solver, and founder of startups.

LINKS

Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q

Youtube clips: https://www.youtube.com/channel/UC-B5x371AzTGgK-_q3U_KfA

Linkedin: https://www.linkedin.com/in/lowell-thompson-2227b074

Twitter: https://twitter.com/LWThompson5

Website: https://www.learningwithlowell.com/

Timestamps / chapters

00:00 Intro Robin Mansukhani

00:45 Defensibility of Deciduous Therapeutics IP

03:25 Buying vs building

05:00 Altos labs

06:00 Time horizon for Deciduous Therapeutics therapies

07:25 Blockers

10:00 Stage of current therapies

11:05 Highs and lows of Deciduous Therapeutics

13:45 Muscle of grit

15:25 Strategies for when feeling low

17:10 Ice baths

19:25 Reading to ground

20:45 Different perspectives

21:45 Hands on leading

24:45 Listening to understand 

26:25 Developing multiple drugs

28:45 When to stop developing new drugs

30:10 T-Cells, senescence

34:30 T cell natural response to senescent cells

35:45 Fibrosis, type 2 diabetes therapy and model

39:00 Type 1 and type 2 diabetes

40:25 Immune response to t-cell therapy

41:25 Resistance and down regulation

44:05 Dosage over time

44:45 Drug interactions / mono therapy

46:45 Drug to drug interactions

49:15 Cutting edge research / data on in-house research on t-cells and senescence 

54:00 Health span and life span

55:45 Vision for future

58:15 Different compared to other senescence / longevity related companies

1:01:45 Platform / future of ”startup”

1:03:30 Mapping future when research can be flawed

1:06:00 Books

1:09:20 On the lookout for people who’ve brought drugs to market

1:10:30 Ways to stay up to date 

1:11:35 Managing Investor relations

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.